# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Yul Brynner (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML020-SYN-TD
- Date: 1983-10-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Simon Achterberg, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine visit, established patient, 40 to 64 years) with CPT 99497 (advance care planning), on the same day

## Chief complaint

Adult preventive visit; rash improving. **S**

## History of present illness

Mr. Brynner is a 63-year-old man with stage IVB adenocarcinoma of the left upper lobe on first-line pembrolizumab every 3 weeks (two cycles so far) and zoledronic acid every 12 weeks, who comes for his yearly preventive visit, timed before the respiratory virus season. The rash seen last week is fading with the triamcinolone cream, and the itching is much less; he has used cetirizine on three nights. He has had no new symptoms of immune-related side effects. His voice is stronger after the injection medialization and voice therapy, and he has begun rehearsing two hours a day; he hopes to rejoin the tour for a few performances a week next month. He saw the palliative care team four weeks ago and found it useful. He completed the health risk assessment before the visit. **S**

| Element | Detail |
|---|---|
| Visit | Adult preventive visit |
| Active treatment | Pembrolizumab every 3 weeks; zoledronic acid every 12 weeks; vitamin D3 daily |
| Interval change | Rash fading on topical steroid; no other immune-related symptoms |
| Work | Rehearsing two hours a day; plans a graded return to the tour |
| Supports | Spouse, company manager, and the palliative care team |

## Health risk assessment

Completed by the patient before the visit and reviewed during the visit. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, apart from tiring by evening |
| Psychosocial | Worried about the future but coping; strong sense of purpose in returning to the stage; supportive spouse and company |
| Tobacco | Former smoker; no tobacco for 12 years |
| Alcohol and drugs | A glass of wine two or three nights a week (AUDIT-C 2); no other drug use |
| Physical activity | Walks 30 minutes most days and does stage warm-ups |
| Nutrition | Eating well; weight stable at about 72 kg |
| Sleep | About seven hours a night; itching woke him twice last week |
| Activities of daily living | Independent |
| Instrumental activities of daily living | Independent; company manager handles travel bookings |
| Home and travel safety | Smoke detectors at home; seat belt always; hotel rooms booked near elevators |
| Falls | None |
| Hearing and vision | Reading glasses; no hearing difficulty |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by evening; no fever, night sweats, or weight loss since starting treatment |
| Eyes | Negative | No redness or change in vision |
| Ears, nose, mouth, and throat | Positive | Voice still slightly breathy after a long rehearsal; no mouth sores |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Respiratory | Positive | Occasional dry cough in the morning; mild breathlessness on two flights of stairs, unchanged |
| Gastrointestinal | Negative | No diarrhea, abdominal pain, or blood in the stool |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No back, hip, or rib pain |
| Integumentary | Positive | Rash fading; mild itch |
| Neurological | Negative | No headache, weakness, or numbness |
| Psychiatric | Negative | Mood steady; PHQ-2 score 1 |
| Endocrine | Negative | No heat or cold intolerance or excessive thirst |

12 systems reviewed. **S**

## Current medications

- Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks **S**
- Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases **S**
- Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid **S**
- Triamcinolone acetonide 0.1% cream, thin layer to the rash twice daily for two weeks (not on the face or skin folds) **S**
- Cetirizine 10 mg oral tablet, one tablet daily as needed for itching **S**

## Allergies

- No known allergy **S**

## Objective

BP 124/76 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 72.3 kg; BMI 22.8 kg/m². All vital signs are synthetic.

PHQ-2: 1; AUDIT-C: 2. All results are synthetic.

## Immunizations given today

- Influenza vaccine, 1983-1984 season **S**
- Pneumococcal conjugate vaccine PCV20, single dose **S**
- Recombinant zoster vaccine, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well, upright, and commanding; weight 72.3 kg, BMI 22.8 |
| Eyes | Pupils equal and reactive; conjunctivae normal |
| Ears, nose, and throat | Voice louder and less breathy than at presentation; oral mucosa normal; good dentition |
| Neck | No supraclavicular or cervical nodes; thyroid not enlarged |
| Cardiovascular | Regular rhythm at 74 per minute; no murmur; no edema |
| Respiratory | Slightly reduced breath sounds at the left apex; no wheeze or crackles |
| Abdomen | Soft and non-tender; no liver enlargement |
| Musculoskeletal | No spinal, pelvic, or rib tenderness |
| Skin | Fading pink macules on the chest and back; no new lesions; no suspicious moles |
| Neurological | Alert and oriented; normal strength and gait |
| Psychiatric | Composed and engaged; good insight |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adult preventive visit completed**. Health risk assessment reviewed and a written prevention plan given, adapted to active treatment for metastatic lung cancer: vaccines are the priority, and screening tests whose benefit takes years are deferred until the first response scan. Depression and alcohol screens negative. **S**
   - Influenza, PCV20, and recombinant zoster dose 1 today.
   - COVID-19 vaccine next week; RSV vaccine at the next visit.
   - Next preventive visit in one year.
2. **Immune-related rash, grade 1, improving** (L27.0). Fading with topical steroid; no blisters or mucosal involvement. **S**
   - Finish the two-week course of triamcinolone, then emollient alone.
   - Cetirizine as needed.
3. **Stage IVB adenocarcinoma of the lung on pembrolizumab** (C34.12). Two cycles given; no other immune-related events; preparing to return to work. **S**
   - Cycle 3 next week after the laboratory panel.
   - Response CT in about four weeks.
   - Palliative care follow-up next month.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Influenza vaccine, this season | Completed today | Inactivated vaccine given today; safe on checkpoint inhibitor therapy |
| Pneumococcal vaccine | Completed today | PCV20 given today; recommended once for all adults 50 and older |
| Recombinant zoster vaccine | Completed today | Dose 1 given today; dose 2 in two to six months |
| COVID-19 vaccine, this season | Due | Recommended; at his pharmacy next week, spaced from today's vaccines at his request |
| RSV vaccine | Due | Recommended at 60 to 74 for adults at increased risk, which his lung cancer confers; planned for the next visit |
| Tetanus, diphtheria, and pertussis booster | Up to date | Tdap six years ago |
| Colorectal cancer screening | Due | Recommended at 45 to 75; deferred by shared decision while he starts treatment for metastatic cancer; to be revisited after the first response scan |
| Prostate cancer screening | Declined | Individual decision at 55 to 69; after discussion he declined PSA testing while on cancer treatment |
| Lung cancer screening | Not indicated | He has lung cancer and is followed with response imaging |
| Abdominal aortic aneurysm screening | Not indicated | One-time ultrasound for men 65 to 75 who have ever smoked; he is 63, and his staging CT showed a normal abdominal aorta |
| Hepatitis C and HIV screening | Up to date | One-time screening for both done in the past, negative |
| Cholesterol screening and statin decision | Due | Deferred by shared decision while he starts treatment for metastatic cancer |
| Diabetes screening | Up to date | Glucose is checked before each pembrolizumab infusion; 94 to 104 mg/dL |
| Blood pressure screening | Completed today | 124/76 mmHg |
| Depression screening | Completed today | PHQ-2 score 1; PHQ-9 4 two weeks ago |
| Unhealthy alcohol use screening | Completed today | AUDIT-C 2, below the risk threshold |
| Tobacco use | Completed today | Former smoker; no tobacco for 12 years |
| Skin examination | Completed today | Rash fading; no suspicious lesions |

## Advance care planning

Voluntary advance care planning discussion of about 30 minutes, with his consent, building on the goals-of-care conversation with the palliative care team. We talked about what metastatic lung cancer can mean, that treatment aims to control it and help him live well for as long as possible rather than to cure it, and why it helps to plan ahead while he is well. He named a health care agent, who is recorded in the chart and not named here, and took a health care proxy form and a living will form home. He said what matters most to him is to keep working on the stage for as long as he can and to be told the truth plainly. He wants full cancer treatment now. He chose not to record other specific treatment preferences today. The plan will be revisited at the first response scan and at any change in his health. **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026), Aether Forge
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Ferrell BR et al., J Clin Oncol 2017;35(1):96-112)
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Cycle 3 of pembrolizumab next week. COVID-19 vaccine at the pharmacy next week. Response CT in about four weeks. RSV vaccine and zoster dose 2 at later visits. Next preventive visit in one year. **S**

